News

Important information

BIOJAMP : A Range of Biosimilars for a Seamless Approach

January 6, 2023
JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes
May 31, 2022
JAMP Pharma covers many therapeutic areas with medicines to treat a large number of diverse indications with close to 300 Rx and OTC molecules.